Teva to Report First Quarter 2016 Financial Results on May 9, 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Guggenheim Remains Bullish Ahead of Teva Pharma's (TEVA) AGN Deal
April 18, 2016 11:38 AM EDTGuggenheim reiterated a Buy rating and $80.00 price target on Teva Pharma (NYSE: TEVA) ahead of a deal close and pipeline catalysts in 2016. The company's AGN generics deal is scheduled to close in June. Guggenheim Cut 2016 EPS estimates $0.35 to $5.17. The decreases in EPS estimates are... More
